Loading company…
Pro-immune develops live microbial drugs and probiotic products for immune diseases.
Pro-immune is a pharmaceutical company founded in 2021 and based in Hangzhou, China. It develops microbiome-based products for autoimmune diseases, including strains PM001, PM002, and PM005 for conditions such as inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis. In May 2024, it closed pre-Series A funding to support strain development and clinical research, its Jibusen Probiotics brand, and R&D and production facilities.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in